Tinzaparin sodium for thrombosis treatment and prevention during pregnancy - 25/08/11
, Lucy A Norris, PhD b, Philip J Steer, FRCOG c, Geoffrey F Savidge, MD a, John Bonnar, FRCOG b
Reprint requests: Mark P. Smith, MBChB FRACP FRCPA, Department of Haematology, Canterbury Health Laboratories, PO Box 151, Christchurch, New Zealand.Abstract |
Objective |
This study was undertaken to assess the pharmacodynamic profile, safety, and efficacy of tinzaparin during pregnancy.
Study design |
Fifty-four pregnant women, 12 for treatment of thrombosis and 42 for thromboprophylaxis, received tinzaparin by once daily injection. Four-hour postdose anti-Xa results were analyzed by use of repeated measures statistical methods.
Results |
One woman (3.4%) on the 175 anti-Xa U/kg dose and three women (20%) on the 50 anti-Xa U/kg dose required a dose increase during the initial dose titration phase to achieve target anti-Xa activity. No thrombotic events occurred.
Conclusion |
The 175 anti-Xa U/kg dose is appropriate for treatment and for high-risk thromboprophylaxis throughout pregnancy. In pregnant women at moderate risk of thrombosis, a higher tinzaparin dose is required than in the nonpregnant state and 75 anti-Xa U/kg appears to be appropriate. The majority of women do not need a dose increase with advancing gestation.
Le texte complet de cet article est disponible en PDF.Keywords : Tinzaparin, pregnancy, pharmacokinetic, low-molecular-weight heparin, thrombosis
Plan
 | LEO Pharma A/S supplied tinzaparin free of charge during this study, funded the cost of laboratory assays, and provided assistance with statistical methods. |
Vol 190 - N° 2
P. 495-501 - février 2004 Retour au numéro
Article précédent
- Genetic influence on prolonged gestation: A population-based Danish twin study
- Maja Laursen, Camilla Bille, Annette W Olesen, Jacob Hjelmborg, Axel Skytthe, Kaare Christensen
- Acute fatty liver of pregnancy associated with pancreatitis: A life-threatening complication
- Julie S. Moldenhauer, John M. O'Brien, John R. Barton, Baha Sibai
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?